Simon A Gayther

List of Publications by Year in Descending Order

229 papers	14,997 citations	64 h-index	116 g-index
245 ext. papers	17,471 ext. citations	9.9 avg, IF	5.2 L-index

#	Paper	IF	Citations
229	A multi-level investigation of the genetic relationship between endometriosis and ovarian cancer histotypes.. *Cell Reports Medicine*, **2022**, 3, 100542	18	5
228	Validated biomarker assays confirm ARID1A loss is confounded with MMR deficiency, CD8 TIL infiltration, and provides no independent prognostic value in endometriosis-associated ovarian carcinomas.. *Journal of Pathology*, **2021**,	9.4	3
227	Predicting master transcription factors from pan-cancer expression data. *Science Advances*, **2021**, 7, eabf6133	14.3	2
226	MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2021**,	5.1	2
225	Single-cell transcriptomics identifies gene expression networks driving differentiation and tumorigenesis in the human fallopian tube. *Cell Reports*, **2021**, 35, 108978	10.6	7
224	Pleiotropy-guided transcriptome imputation from normal and tumor tissues identifies candidate susceptibility genes for breast and ovarian cancer. *Human Genetics and Genomics Advances*, **2021**, 2, 100042-100042	0.8	2
223	The predictive ability of the 313 variant-based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant. *Genetics in Medicine*, **2021**, 23, 1726-1737	8.1	2
222	Population-based targeted sequencing of 54 candidate genes identifies as a susceptibility gene for high-grade serous ovarian cancer. *Journal of Medical Genetics*, **2021**, 58, 305-313	5.8	12
221	A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers. *Nature Communications*, **2021**, 12, 1078	17.4	4
220	Risks and Function of Breast Cancer Susceptibility Alleles. *Cancers*, **2021**, 13,	6.6	1
219	Human iPSC-derived fallopian tube organoids with BRCA1 mutation recapitulate early-stage carcinogenesis.. *Cell Reports*, **2021**, 37, 110146	10.6	0
218	Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. *Nature Genetics*, **2020**, 52, 572-581	36.3	76
217	Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE). *Clinical Cancer Research*, **2020**, 26, 5411-5423	12.9	21
216	Clinical and pathological associations of PTEN expression in ovarian cancer: a multicentre study from the Ovarian Tumour Tissue Analysis Consortium. *British Journal of Cancer*, **2020**, 123, 793-802	8.7	16
215	Menopausal hormone therapy prior to the diagnosis of ovarian cancer is associated with improved survival. *Gynecologic Oncology*, **2020**, 158, 702-709	4.9	5
214	Assessment of polygenic architecture and risk prediction based on common variants across fourteen cancers. *Nature Communications*, **2020**, 11, 3353	17.4	32
213	Ovarian and Breast Cancer Risks Associated With Pathogenic Variants in RAD51C and RAD51D. *Journal of the National Cancer Institute*, **2020**, 112, 1242-1250	9.7	51

212	Lineage-Specific Epigenomic and Genomic Activation of Oncogene HNF4A Promotes Gastrointestinal Adenocarcinomas. *Cancer Research*, **2020**, 80, 2722-2736	10.1	14
211	Non-coding somatic mutations converge on the PAX8 pathway in ovarian cancer. *Nature Communications*, **2020**, 11, 2020	17.4	17
210	Identification of novel epithelial ovarian cancer loci in women of African ancestry. *International Journal of Cancer*, **2020**, 146, 2987-2998	7.5	8
209	Ovarian Cancer Risk Variants Are Enriched in Histotype-Specific Enhancers and Disrupt Transcription Factor Binding Sites. *American Journal of Human Genetics*, **2020**, 107, 622-635	11	5
208	Prostate cancer reactivates developmental epigenomic programs during metastatic progression. *Nature Genetics*, **2020**, 52, 790-799	36.3	62
207	Rare Germline Genetic Variants and the Risks of Epithelial Ovarian Cancer. *Cancers*, **2020**, 12,	6.6	5
206	Offspring sex and risk of epithelial ovarian cancer: a multinational pooled analysis of 12 case-control studies. *European Journal of Epidemiology*, **2020**, 35, 1025-1042	12.1	2
205	Master transcription factors form interconnected circuitry and orchestrate transcriptional networks in oesophageal adenocarcinoma. *Gut*, **2020**, 69, 630-640	19.2	27
204	Shared heritability and functional enrichment across six solid cancers. *Nature Communications*, **2019**, 10, 431	17.4	45
203	A combination of the immunohistochemical markers CK7 and SATB2 is highly sensitive and specific for distinguishing primary ovarian mucinous tumors from colorectal and appendiceal metastases. *Modern Pathology*, **2019**, 32, 1834-1846	9.8	21
202	Evaluation of vitamin D biosynthesis and pathway target genes reveals UGT2A1/2 and EGFR polymorphisms associated with epithelial ovarian cancer in African American Women. *Cancer Medicine*, **2019**, 8, 2503-2513	4.8	4
201	A transcriptome-wide association study of high-grade serous epithelial ovarian cancer identifies new susceptibility genes and splice variants. *Nature Genetics*, **2019**, 51, 815-823	36.3	33
200	Genome-wide association studies identify susceptibility loci for epithelial ovarian cancer in east Asian women. *Gynecologic Oncology*, **2019**, 153, 343-355	4.9	16
199	Super-Enhancer-Associated LncRNA UCA1 Interacts Directly with AMOT to Activate YAP Target Genes in Epithelial Ovarian Cancer. *IScience*, **2019**, 17, 242-255	6.1	38
198	GENAVi: a shiny web application for gene expression normalization, analysis and visualization. *BMC Genomics*, **2019**, 20, 745	4.5	10
197	A Study of High-Grade Serous Ovarian Cancer Origins Implicates the SOX18 Transcription Factor in Tumor Development. *Cell Reports*, **2019**, 29, 3726-3735.e4	10.6	19
196	Molecular signatures of X chromosome inactivation and associations with clinical outcomes in epithelial ovarian cancer. *Human Molecular Genetics*, **2019**, 28, 1331-1342	5.6	11
195	Functional Analysis and Fine Mapping of the 9p22.2 Ovarian Cancer Susceptibility Locus. *Cancer Research*, **2019**, 79, 467-481	10.1	11

194	A comprehensive gene-environment interaction analysis in Ovarian Cancer using genome-wide significant common variants. *International Journal of Cancer*, **2019**, 144, 2192-2205	7.5	11
193	Genetic Data from Nearly 63,000 Women of European Descent Predicts DNA Methylation Biomarkers and Epithelial Ovarian Cancer Risk. *Cancer Research*, **2019**, 79, 505-517	10.1	28
192	Adult height is associated with increased risk of ovarian cancer: a Mendelian randomisation study. *British Journal of Cancer*, **2018**, 118, 1123-1129	8.7	10
191	Cost-effectiveness of Population-Based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 Mutation Testing in Unselected General Population Women. *Journal of the National Cancer Institute*, **2018**, 110, 714-725	9.7	92
190	Assessment of moderate coffee consumption and risk of epithelial ovarian cancer: a Mendelian randomization study. *International Journal of Epidemiology*, **2018**, 47, 450-459	7.8	8
189	Robust Tests for Additive Gene-Environment Interaction in Case-Control Studies Using Gene-Environment Independence. *American Journal of Epidemiology*, **2018**, 187, 366-377	3.8	7
188	Common Genetic Variation and Susceptibility to Ovarian Cancer: Current Insights and Future Directions. *Cancer Epidemiology Biomarkers and Prevention*, **2018**, 27, 395-404	4	25
187	Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study. *Journal of Pathology: Clinical Research*, **2018**, 4, 250-261	5.3	38
186	A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. *Cancer Research*, **2018**, 78, 5419-5430	10.1	32
185	Variants in genes encoding small GTPases and association with epithelial ovarian cancer susceptibility. *PLoS ONE*, **2018**, 13, e0197561	3.7	9
184	rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology. *International Journal of Molecular Sciences*, **2018**, 19,	6.3	3
183	Large-scale transcriptome-wide association study identifies new prostate cancer risk regions. *Nature Communications*, **2018**, 9, 4079	17.4	65
182	Evaluation of polygenic risk scores for ovarian cancer risk prediction in a prospective cohort study. *Journal of Medical Genetics*, **2018**, 55, 546-554	5.8	30
181	Transcriptomic Characterization of Endometrioid, Clear Cell, and High-Grade Serous Epithelial Ovarian Carcinoma. *Cancer Epidemiology Biomarkers and Prevention*, **2018**, 27, 1101-1109	4	9
180	Enrichment of putative PAX8 target genes at serous epithelial ovarian cancer susceptibility loci. *British Journal of Cancer*, **2017**, 116, 524-535	8.7	18
179	Cigarette smoking is associated with adverse survival among women with ovarian cancer: Results from a pooled analysis of 19 studies. *International Journal of Cancer*, **2017**, 140, 2422-2435	7.5	18
178	Down-regulation of ARID1A is sufficient to initiate neoplastic transformation along with epigenetic reprogramming in non-tumorigenic endometriotic cells. *Cancer Letters*, **2017**, 401, 11-19	9.9	27
177	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. *Nature Genetics*, **2017**, 49, 680-691	36.3	190

176	Use of common analgesic medications and ovarian cancer survival: results from a pooled analysis in the Ovarian Cancer Association Consortium. *British Journal of Cancer*, **2017**, 116, 1223-1228	8.7	11
175	Integration of Population-Level Genotype Data with Functional Annotation Reveals Over-Representation of Long Noncoding RNAs at Ovarian Cancer Susceptibility Loci. *Cancer Epidemiology Biomarkers and Prevention*, **2017**, 26, 116-125	4	5
174	Genetic epidemiology of ovarian cancer and prospects for polygenic risk prediction. *Gynecologic Oncology*, **2017**, 147, 705-713	4.9	48
173	History of Comorbidities and Survival of Ovarian Cancer Patients, Results from the Ovarian Cancer Association Consortium. *Cancer Epidemiology Biomarkers and Prevention*, **2017**, 26, 1470-1473	4	8
172	An integrative approach to assess X-chromosome inactivation using allele-specific expression with applications to epithelial ovarian cancer. *Genetic Epidemiology*, **2017**, 41, 898-914	2.6	7
171	Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. *Breast Cancer Research and Treatment*, **2017**, 161, 117-134	4.4	15
170	No Evidence That Genetic Variation in the Myeloid-Derived Suppressor Cell Pathway Influences Ovarian Cancer Survival. *Cancer Epidemiology Biomarkers and Prevention*, **2017**, 26, 420-424	4	3
169	The OncoArray Consortium: A Network for Understanding the Genetic Architecture of Common Cancers. *Cancer Epidemiology Biomarkers and Prevention*, **2017**, 26, 126-135	4	183
168	Germline whole exome sequencing and large-scale replication identifies as a likely high grade serous ovarian cancer susceptibility gene. *Oncotarget*, **2017**, 8, 50930-50940	3.3	30
167	Characterization of fusion genes in common and rare epithelial ovarian cancer histologic subtypes. *Oncotarget*, **2017**, 8, 46891-46899	3.3	17
166	The PAX8 cistrome in epithelial ovarian cancer. *Oncotarget*, **2017**, 8, 108316-108332	3.3	24
165	No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. *Gynecologic Oncology*, **2016**, 141, 386-401	4.9	15
164	A splicing variant of TERT identified by GWAS interacts with menopausal estrogen therapy in risk of ovarian cancer. *International Journal of Cancer*, **2016**, 139, 2646-2654	7.5	6
163	Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types. *Cancer Discovery*, **2016**, 6, 1052-67	24.4	104
162	Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer. *Nature Communications*, **2016**, 7, 11375	17.4	64
161	Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus. *Nature Communications*, **2016**, 7, 12675	17.4	53
160	Assessment of Multifactor Gene-Environment Interactions and Ovarian Cancer Risk: Candidate Genes, Obesity, and Hormone-Related Risk Factors. *Cancer Epidemiology Biomarkers and Prevention*, **2016**, 25, 780-90	4	8
159	PPM1D Mosaic Truncating Variants in Ovarian Cancer Cases May Be Treatment-Related Somatic Mutations. *Journal of the National Cancer Institute*, **2016**, 108,	9.7	34

158	The association between socioeconomic status and tumour stage at diagnosis of ovarian cancer: A pooled analysis of 18 case-control studies. *Cancer Epidemiology*, **2016**, 41, 71-9	2.8	17
157	Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. *Nature Genetics*, **2016**, 48, 374-86	36.3	93
156	Investigation of Exomic Variants Associated with Overall Survival in Ovarian Cancer. *Cancer Epidemiology Biomarkers and Prevention*, **2016**, 25, 446-54	4	6
155	BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. *Journal of the National Cancer Institute*, **2016**, 108,	9.7	65
154	Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer. *Oncotarget*, **2016**, 7, 69097-69110	3.3	4
153	Inherited variants affecting RNA editing may contribute to ovarian cancer susceptibility: results from a large-scale collaboration. *Oncotarget*, **2016**, 7, 72381-72394	3.3	11
152	HNF1B variants associate with promoter methylation and regulate gene networks activated in prostate and ovarian cancer. *Oncotarget*, **2016**, 7, 74734-74746	3.3	31
151	Adult body mass index and risk of ovarian cancer by subtype: a Mendelian randomization study. *International Journal of Epidemiology*, **2016**, 45, 884-95	7.8	45
150	Association Between Menopausal Estrogen-Only Therapy and Ovarian Carcinoma Risk. *Obstetrics and Gynecology*, **2016**, 127, 828-836	4.9	24
149	Exome genotyping arrays to identify rare and low frequency variants associated with epithelial ovarian cancer risk. *Human Molecular Genetics*, **2016**, 25, 3600-3612	5.6	9
148	Assessing the genetic architecture of epithelial ovarian cancer histological subtypes. *Human Genetics*, **2016**, 135, 741-56	6.3	18
147	The BRCA1-Δ11q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapeutic Resistance to PARP Inhibition and Cisplatin. *Cancer Research*, **2016**, 76, 2778-90	10.1	136
146	Association of vitamin D levels and risk of ovarian cancer: a Mendelian randomization study. *International Journal of Epidemiology*, **2016**, 45, 1619-1630	7.8	77
145	Telomere structure and maintenance gene variants and risk of five cancer types. *International Journal of Cancer*, **2016**, 139, 2655-2670	7.5	30
144	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. *Nature Genetics*, **2015**, 47, 164-71	36.3	177
143	PAX8 expression in ovarian surface epithelial cells. *Human Pathology*, **2015**, 46, 948-56	3.7	27
142	Network-Based Integration of GWAS and Gene Expression Identifies a HOX-Centric Network Associated with Serous Ovarian Cancer Risk. *Cancer Epidemiology Biomarkers and Prevention*, **2015**, 24, 1574-84	4	24
141	Genome-wide Analysis Identifies Novel Loci Associated with Ovarian Cancer Outcomes: Findings from the Ovarian Cancer Association Consortium. *Clinical Cancer Research*, **2015**, 21, 5264-76	12.9	24

140	Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. *JAMA - Journal of the American Medical Association*, **2015**, 313, 1347-61	27.4	286
139	NPPB is a novel candidate biomarker expressed by cancer-associated fibroblasts in epithelial ovarian cancer. *International Journal of Cancer*, **2015**, 136, 1390-401	7.5	17
138	Cis-eQTL analysis and functional validation of candidate susceptibility genes for high-grade serous ovarian cancer. *Nature Communications*, **2015**, 6, 8234	17.4	40
137	Common variants at the CHEK2 gene locus and risk of epithelial ovarian cancer. *Carcinogenesis*, **2015**, 36, 1341-53	4.6	20
136	CAUSEL: an epigenome- and genome-editing pipeline for establishing function of noncoding GWAS variants. *Nature Medicine*, **2015**, 21, 1357-63	50.5	65
135	Shared genetics underlying epidemiological association between endometriosis and ovarian cancer. *Human Molecular Genetics*, **2015**, 24, 5955-64	5.6	48
134	Contribution of Germline Mutations in the RAD51B, RAD51C, and RAD51D Genes to Ovarian Cancer in the Population. *Journal of Clinical Oncology*, **2015**, 33, 2901-7	2.2	200
133	Germline Mutations in the BRIP1, BARD1, PALB2, and NBN Genes in Women With Ovarian Cancer. *Journal of the National Cancer Institute*, **2015**, 107,	9.7	239
132	Stromal Expression of Fibroblast Activation Protein Alpha (FAP) Predicts Platinum Resistance and Shorter Recurrence in patients with Epithelial Ovarian Cancer. *Cancer Microenvironment*, **2015**, 8, 23-31	6.1	39
131	Epithelial-Mesenchymal Transition (EMT) Gene Variants and Epithelial Ovarian Cancer (EOC) Risk. *Genetic Epidemiology*, **2015**, 39, 689-97	2.6	18
130	Identification of novel candidate biomarkers of epithelial ovarian cancer by profiling the secretomes of three-dimensional genetic models of ovarian carcinogenesis. *International Journal of Cancer*, **2015**, 137, 1806-17	7.5	14
129	Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) Risk. *PLoS ONE*, **2015**, 10, e0128106	3.7	15
128	Molecular Analysis of Mixed Endometrioid and Serous Adenocarcinoma of the Endometrium. *PLoS ONE*, **2015**, 10, e0130909	3.7	20
127	Cell-type-specific enrichment of risk-associated regulatory elements at ovarian cancer susceptibility loci. *Human Molecular Genetics*, **2015**, 24, 3595-607	5.6	32
126	Germline mutation in BRCA1 or BRCA2 and ten-year survival for women diagnosed with epithelial ovarian cancer. *Clinical Cancer Research*, **2015**, 21, 652-7	12.9	107
125	A functional variant in HOXA11-AS, a novel long non-coding RNA, inhibits the oncogenic phenotype of epithelial ovarian cancer. *Oncotarget*, **2015**, 6, 34745-57	3.3	92
124	Common Genetic Variation in Circadian Rhythm Genes and Risk of Epithelial Ovarian Cancer (EOC). *Journal of Genetics and Genome Research*, **2015**, 2,		22
123	Genome-wide association study of subtype-specific epithelial ovarian cancer risk alleles using pooled DNA. *Human Genetics*, **2014**, 133, 481-97	6.3	21

122	The contribution of deleterious germline mutations in BRCA1, BRCA2 and the mismatch repair genes to ovarian cancer in the population. *Human Molecular Genetics*, **2014**, 23, 4703-9	5.6	90
121	Kernel canonical correlation analysis for assessing gene-gene interactions and application to ovarian cancer. *European Journal of Human Genetics*, **2014**, 22, 126-31	5.3	27
120	Expression QTL-based analyses reveal candidate causal genes and loci across five tumor types. *Human Molecular Genetics*, **2014**, 23, 5294-302	5.6	61
119	Variation in NF-Β signaling pathways and survival in invasive epithelial ovarian cancer. *Cancer Epidemiology Biomarkers and Prevention*, **2014**, 23, 1421-7	4	11
118	Src as a novel therapeutic target for endometriosis. *Gynecologic Oncology*, **2014**, 135, 100-7	4.9	7
117	Risk of ovarian cancer and the NF-Β pathway: genetic association with IL1A and TNFSF10. *Cancer Research*, **2014**, 74, 852-61	10.1	36
116	Large-scale evaluation of common variation in regulatory T cell-related genes and ovarian cancer outcome. *Cancer Immunology Research*, **2014**, 2, 332-40	12.5	20
115	Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. *Lancet Oncology, The*, **2013**, 14, 853-62	21.7	248
114	GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. *Nature Genetics*, **2013**, 45, 362-70, 370e1-2	36.3	267
113	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. *Nature Genetics*, **2013**, 45, 371-84, 384e1-2	36.3	422
112	In vitro three-dimensional modeling of fallopian tube secretory epithelial cells. *BMC Cell Biology*, **2013**, 14, 43		35
111	Cigarette smoking and risk of ovarian cancer: a pooled analysis of 21 case-control studies. *Cancer Causes and Control*, **2013**, 24, 989-1004	2.8	69
110	The sex hormone system in carriers of BRCA1/2 mutations: a case-control study. *Lancet Oncology, The*, **2013**, 14, 1226-32	21.7	73
109	Biomarker-based ovarian carcinoma typing: a histologic investigation in the ovarian tumor tissue analysis consortium. *Cancer Epidemiology Biomarkers and Prevention*, **2013**, 22, 1677-86	4	53
108	Combined and interactive effects of environmental and GWAS-identified risk factors in ovarian cancer. *Cancer Epidemiology Biomarkers and Prevention*, **2013**, 22, 880-90	4	37
107	Obesity and risk of ovarian cancer subtypes: evidence from the Ovarian Cancer Association Consortium. *Endocrine-Related Cancer*, **2013**, 20, 251-62	5.7	135
106	Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. *Nature Communications*, **2013**, 4, 1628	17.4	124
105	Analysis of over 10,000 Cases finds no association between previously reported candidate polymorphisms and ovarian cancer outcome. *Cancer Epidemiology Biomarkers and Prevention*, **2013**, 22, 987-92	4	20

104	Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31. *Nature Communications*, **2013**, 4, 1627	17.4	85
103	Inherited variants in regulatory T cell genes and outcome of ovarian cancer. *PLoS ONE*, **2013**, 8, e53903	3.7	19
102	Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers. *Breast Cancer Research*, **2012**, 14, R33	8.3	70
101	Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. *Human Mutation*, **2012**, 33, 690-702	4.7	31
100	Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. *JAMA - Journal of the American Medical Association*, **2012**, 307, 382-90	27.4	427
99	Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies. *Lancet Oncology, The*, **2012**, 13, 385-94	21.7	612
98	ABO blood group and risk of epithelial ovarian cancer within the Ovarian Cancer Association Consortium. *Cancer Causes and Control*, **2012**, 23, 1805-10	2.8	27
97	Gene set analysis of survival following ovarian cancer implicates macrolide binding and intracellular signaling genes. *Cancer Epidemiology Biomarkers and Prevention*, **2012**, 21, 529-36	4	7
96	Common breast cancer susceptibility variants in LSP1 and RAD51L1 are associated with mammographic density measures that predict breast cancer risk. *Cancer Epidemiology Biomarkers and Prevention*, **2012**, 21, 1156-66	4	92
95	Ovarian cancer risk associated with inherited inflammation-related variants. *Cancer Research*, **2012**, 72, 1064-9	10.1	35
94	Common variants at the 19p13.1 and ZNF365 loci are associated with ER subtypes of breast cancer and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. *Cancer Epidemiology Biomarkers and Prevention*, **2012**, 21, 645-57	4	44
93	Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). *Cancer Epidemiology Biomarkers and Prevention*, **2012**, 21, 134-47	4	411
92	Genome-wide association study for ovarian cancer susceptibility using pooled DNA. *Twin Research and Human Genetics*, **2012**, 15, 615-623	2.2	8
91	Progesterone receptor gene polymorphisms and risk of endometriosis: results from an international collaborative effort. *Fertility and Sterility*, **2011**, 95, 40-5	4.8	18
90	Recruitment of newly diagnosed ovarian cancer patients proved challenging in a multicentre biobanking study. *Journal of Clinical Epidemiology*, **2011**, 64, 525-30	5.7	27
89	Functional polymorphisms in the TERT promoter are associated with risk of serous epithelial ovarian and breast cancers. *PLoS ONE*, **2011**, 6, e24987	3.7	41
88	Principles for the post-GWAS functional characterization of cancer risk loci. *Nature Genetics*, **2011**, 43, 513-8	36.3	326
87	Vitamin D receptor rs2228570 polymorphism and invasive ovarian carcinoma risk: pooled analysis in five studies within the Ovarian Cancer Association Consortium. *International Journal of Cancer*, **2011**, 128, 936-43	7.5	44

86	Common alleles in candidate susceptibility genes associated with risk and development of epithelial ovarian cancer. *International Journal of Cancer*, **2011**, 128, 2063-74	7.5	49
85	Genetic variation in insulin-like growth factor 2 may play a role in ovarian cancer risk. *Human Molecular Genetics*, **2011**, 20, 2263-72	5.6	18
84	Prostate cancer susceptibility polymorphism rs2660753 is not associated with invasive ovarian cancer. *Cancer Epidemiology Biomarkers and Prevention*, **2011**, 20, 1028-31	4	
83	The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing. *Clinical Cancer Research*, **2011**, 17, 3742-50	12.9	45
82	LIN28B polymorphisms influence susceptibility to epithelial ovarian cancer. *Cancer Research*, **2011**, 71, 3896-903	10.1	70
81	Modelling genetic and clinical heterogeneity in epithelial ovarian cancers. *Carcinogenesis*, **2011**, 32, 1540-46	4.6	33
80	Common variants of the BRCA1 wild-type allele modify the risk of breast cancer in BRCA1 mutation carriers. *Human Molecular Genetics*, **2011**, 20, 4732-47	5.6	21
79	MicroRNA processing and binding site polymorphisms are not replicated in the Ovarian Cancer Association Consortium. *Cancer Epidemiology Biomarkers and Prevention*, **2011**, 20, 1793-7	4	18
78	Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers. *Journal of the National Cancer Institute*, **2011**, 103, 105-16	9.7	37
77	Polymorphisms in stromal genes and susceptibility to serous epithelial ovarian cancer: a report from the Ovarian Cancer Association Consortium. *PLoS ONE*, **2011**, 6, e19642	3.7	4
76	Estrogen receptor beta rs1271572 polymorphism and invasive ovarian carcinoma risk: pooled analysis within the Ovarian Cancer Association Consortium. *PLoS ONE*, **2011**, 6, e20703	3.7	20
75	Common variants at 19p13 are associated with susceptibility to ovarian cancer. *Nature Genetics*, **2010**, 42, 880-4	36.3	210
74	A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. *Nature Genetics*, **2010**, 42, 874-9	36.3	277
73	A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. *Nature Genetics*, **2010**, 42, 885-92	36.3	276
72	Principles for the post-GWAS functional characterisation of risk loci. *Nature Precedings*, **2010**,		1
71	Polymorphism in the GALNT1 gene and epithelial ovarian cancer in non-Hispanic white women: the Ovarian Cancer Association Consortium. *Cancer Epidemiology Biomarkers and Prevention*, **2010**, 19, 600-4	4	20
70	Genetic variation in TYMS in the one-carbon transfer pathway is associated with ovarian carcinoma types in the Ovarian Cancer Association Consortium. *Cancer Epidemiology Biomarkers and Prevention*, **2010**, 19, 1822-30	4	22
69	Evaluation of candidate stromal epithelial cross-talk genes identifies association between risk of serous ovarian cancer and TERT, a cancer susceptibility "hot-spot". *PLoS Genetics*, **2010**, 6, e1001016	6	42

68	ESR1/SYNE1 polymorphism and invasive epithelial ovarian cancer risk: an Ovarian Cancer Association Consortium study. *Cancer Epidemiology Biomarkers and Prevention*, **2010**, 19, 245-50	4	64
67	Senescent fibroblasts promote neoplastic transformation of partially transformed ovarian epithelial cells in a three-dimensional model of early stage ovarian cancer. *Neoplasia*, **2010**, 12, 317-25	6.4	66
66	Microcell-mediated chromosome transfer identifies EPB41L3 as a functional suppressor of epithelial ovarian cancers. *Neoplasia*, **2010**, 12, 579-89	6.4	32
65	The inherited genetics of ovarian and endometrial cancer. *Current Opinion in Genetics and Development*, **2010**, 20, 231-8	4.9	47
64	Age-dependent DNA methylation of genes that are suppressed in stem cells is a hallmark of cancer. *Genome Research*, **2010**, 20, 440-6	9.7	638
63	Vascular endothelial growth factor gene polymorphisms and ovarian cancer survival. *Gynecologic Oncology*, **2010**, 119, 479-83	4.9	25
62	A polymorphism in the GALNT2 gene and ovarian cancer risk in four population based case-control studies. *International Journal of Molecular Epidemiology and Genetics*, **2010**, 1, 272-7	0.9	7
61	Association between invasive ovarian cancer susceptibility and 11 best candidate SNPs from breast cancer genome-wide association study. *Human Molecular Genetics*, **2009**, 18, 2297-304	5.6	37
60	Functional complementation studies identify candidate genes and common genetic variants associated with ovarian cancer survival. *Human Molecular Genetics*, **2009**, 18, 1869-78	5.6	16
59	Single nucleotide polymorphisms in the TP53 region and susceptibility to invasive epithelial ovarian cancer. *Cancer Research*, **2009**, 69, 2349-57	10.1	52
58	Chromosomes 6 and 18 induce neoplastic suppression in epithelial ovarian cancer cells. *International Journal of Cancer*, **2009**, 124, 1037-44	7.5	10
57	The clonal evolution of metastases from primary serous epithelial ovarian cancers. *International Journal of Cancer*, **2009**, 124, 1579-86	7.5	53
56	A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. *Nature Genetics*, **2009**, 41, 996-1000	36.3	240
55	Risk of ovarian cancer in women with first-degree relatives with cancer. *Acta Obstetricia Et Gynecologica Scandinavica*, **2009**, 88, 449-56	3.8	13
54	Role of genetic polymorphisms and ovarian cancer susceptibility. *Molecular Oncology*, **2009**, 3, 171-81	7.9	59
53	The contribution of BRCA1 and BRCA2 to ovarian cancer. *Molecular Oncology*, **2009**, 3, 138-50	7.9	125
52	Association between common germline genetic variation in 94 candidate genes or regions and risks of invasive epithelial ovarian cancer. *PLoS ONE*, **2009**, 4, e5983	3.7	33
51	An epigenetic signature in peripheral blood predicts active ovarian cancer. *PLoS ONE*, **2009**, 4, e8274	3.7	245

50	Mismatch repair gene polymorphisms and survival in invasive ovarian cancer patients. *European Journal of Cancer*, **2008**, 44, 2259-65	7.5	20
49	Predicting clinical outcome in patients diagnosed with synchronous ovarian and endometrial cancer. *Clinical Cancer Research*, **2008**, 14, 5840-8	12.9	33
48	Effects of common germ-line genetic variation in cell cycle genes on ovarian cancer survival. *Clinical Cancer Research*, **2008**, 14, 1090-5	12.9	24
47	The effects of common genetic variants in oncogenes on ovarian cancer survival. *Clinical Cancer Research*, **2008**, 14, 5833-9	12.9	30
46	BRCA1 and BRCA2 mutation prevalence and clinical characteristics of a population-based series of ovarian cancer cases from Denmark. *Clinical Cancer Research*, **2008**, 14, 3761-7	12.9	77
45	Association study of prostate cancer susceptibility variants with risks of invasive ovarian, breast, and colorectal cancer. *Cancer Research*, **2008**, 68, 8837-42	10.1	10
44	Multiple loci with different cancer specificities within the 8q24 gene desert. *Journal of the National Cancer Institute*, **2008**, 100, 962-6	9.7	283
43	Protein expression levels of carcinoembryonic antigen (CEA) in Danish ovarian cancer patients: from the Danish SMALOVASovarian cancer study. *Pathology*, **2008**, 40, 487-92	1.6	18
42	Consortium analysis of 7 candidate SNPs for ovarian cancer. *International Journal of Cancer*, **2008**, 123, 380-388	7.5	66
41	Distribution of p53 expression in tissue from 774 Danish ovarian tumour patients and its prognostic significance in ovarian carcinomas. *Apmis*, **2008**, 116, 400-9	3.4	16
40	Tagging single nucleotide polymorphisms in the BRIP1 gene and susceptibility to breast and ovarian cancer. *PLoS ONE*, **2007**, 2, e268	3.7	47
39	Contribution of BRCA1 and BRCA2 mutations to inherited ovarian cancer. *Human Mutation*, **2007**, 28, 1207-15	4.7	67
38	Screening for the BRCA1-ins6kbEx13 mutation: potential for misdiagnosis. Mutation in brief #964. Online. *Human Mutation*, **2007**, 28, 525-6	4.7	8
37	CA125 expression pattern, prognosis and correlation with serum CA125 in ovarian tumor patients. From The Danish "MALOVA" Ovarian Cancer Study. *Gynecologic Oncology*, **2007**, 104, 508-15	4.9	90
36	Expression level of Wilms tumor 1 (WT1) protein has limited prognostic value in epithelial ovarian cancer: from the Danish "MALOVA" ovarian cancer study. *Gynecologic Oncology*, **2007**, 106, 318-24	4.9	18
35	Tagging single nucleotide polymorphisms in cell cycle control genes and susceptibility to invasive epithelial ovarian cancer. *Cancer Research*, **2007**, 67, 3027-35	10.1	75
34	Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients: from the SMALOVASovarian cancer study. *Oncology Reports*, **2007**, 18, 1051-9	3.5	66
33	Common variants in RB1 gene and risk of invasive ovarian cancer. *Cancer Research*, **2006**, 66, 10220-6	10.1	34

32	Common variants in mismatch repair genes and risk of invasive ovarian cancer. *Carcinogenesis*, **2006**, 27, 2235-42	4.6	64
31	Ovarian cancer aetiology: facts and fiction. *Journal of Family Planning and Reproductive Health Care*, **2006**, 32, 82-6		4
30	Genetic mutations in gynaecological cancers. *Reviews in Gynaecological and Perinatal Practice*, **2006**, 6, 115-125		3
29	Ovarian cancer and genetic susceptibility in relation to the BRCA1 and BRCA2 genes. Occurrence, clinical importance and intervention. *Acta Obstetricia Et Gynecologica Scandinavica*, **2006**, 85, 93-105	3.8	42
28	Polymorphisms in DNA repair genes and epithelial ovarian cancer risk. *International Journal of Cancer*, **2005**, 117, 611-8	7.5	112
27	A molecular genetic and statistical approach for the diagnosis of dual-site cancers. *Journal of the National Cancer Institute*, **2004**, 96, 1441-6	9.7	39
26	A modified medium that significantly improves the growth of human normal ovarian surface epithelial (OSE) cells in vitro. *Laboratory Investigation*, **2004**, 84, 923-31	5.9	30
25	Histopathology, FIGO stage, and BRCA mutation status of ovarian cancers from the Gilda Radner Familial Ovarian Cancer Registry. *International Journal of Gynecological Pathology*, **2004**, 23, 29-34	3.2	68
24	Two percent of men with early-onset prostate cancer harbor germline mutations in the BRCA2 gene. *American Journal of Human Genetics*, **2003**, 72, 1-12	11	293
23	BRCA1/2 mutation status influences somatic genetic progression in inherited and sporadic epithelial ovarian cancer cases. *Cancer Research*, **2003**, 63, 417-23	10.1	30
22	Apparent human BRCA1 knockout caused by mispriming during polymerase chain reaction: implications for genetic testing. *Genes Chromosomes and Cancer*, **2001**, 31, 96-8	5	25
21	Risk models for familial ovarian and breast cancer. *Genetic Epidemiology*, **2000**, 18, 173-90	2.6	128
20	Frequent loss of BRCA1 mRNA and protein expression in sporadic ovarian cancers. *International Journal of Cancer*, **2000**, 87, 317-21	7.5	77
19	Mutations truncating the EP300 acetylase in human cancers. *Nature Genetics*, **2000**, 24, 300-3	36.3	482
18	Idiopathic slow-transit constipation is not associated with mutations of the RET proto-oncogene or GDNF. *Diseases of the Colon and Rectum*, **2000**, 43, 851-7	3.1	12
17	Increased frequency of TP53 mutations in BRCA1 and BRCA2 ovarian tumours. *Genes Chromosomes and Cancer*, **1999**, 25, 91-6	5	64
16	The contribution of germline BRCA1 and BRCA2 mutations to familial ovarian cancer: no evidence for other ovarian cancer-susceptibility genes. *American Journal of Human Genetics*, **1999**, 65, 1021-9	11	109
15	The genetics of inherited breast cancer. *Journal of Mammary Gland Biology and Neoplasia*, **1998**, 3, 365-76	2.4	26

14	Identification of a novel splice-site mutation of the BRCA1 gene in two breast cancer families: screening reveals low frequency in Icelandic breast cancer patients. *Human Mutation*, **1998**, Suppl 1, S195-7	4.7	28
13	Clues to the function of the tumour susceptibility gene BRCA2. *Disease Markers*, **1998**, 14, 1-8	3.2	23
12	Contribution of BRCA1 mutations to ovarian cancer. *New England Journal of Medicine*, **1997**, 336, 1125-30	59.2	208
11	Aberrant splicing of the TSG101 and FHIT genes occurs frequently in multiple malignancies and in normal tissues and mimics alterations previously described in tumours. *Oncogene*, **1997**, 15, 2119-26	9.2	75
10	Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene. *Nature Genetics*, **1997**, 15, 103-5	36.3	377
9	A breast/ovarian cancer patient with germline mutations in both BRCA1 and BRCA2. *Nature Genetics*, **1997**, 15, 14-5	36.3	60
8	Mutations of the BRCA1 and BRCA2 genes and the possibilities for predictive testing. *Trends in Molecular Medicine*, **1997**, 3, 168-74		24
7	A polymorphic stop codon in BRCA2. *Nature Genetics*, **1996**, 14, 253-4	36.3	136
6	Breast cancer information on the web. *Nature Genetics*, **1995**, 11, 238-9	36.3	30
5	Germline mutations of the BRCA1 gene in breast and ovarian cancer families provide evidence for a genotype-phenotype correlation. *Nature Genetics*, **1995**, 11, 428-33	36.3	439
4	A gene (DLG2) located at 17q12-q21 encodes a new homologue of the Drosophila tumor suppressor dlg-A. *Genomics*, **1995**, 28, 25-31	4.3	31
3	Localisation of the human blue cone pigment gene to chromosome band 7q31.3-32. *Human Genetics*, **1994**, 93, 79-80	6.3	13
2	Multi-Tissue Transcriptome-Wide Association Study Identifies 26 Novel Candidate Susceptibility Genes for High Grade Serous Epithelial Ovarian Cancer		2
1	Integrated Molecular Profiling Studies to Characterize the Cellular Origins of High-Grade Serous Ovarian Cancer		6